TET2 and acute myeloid leukemia: Among patients with AML, the study of Lin and colleagues made up a part of heterogeneity due to its outlier of HR for OS according to the sensitivity test, but it shouldn’t be excluded for the following reasons: At first, the sample size of cases from the entire cohort was adequate as well as the number of cases with TET2 mutation; Second, the maximum follow-up period of this study was around 120 months, which was long enough to diminish the bias; Next, the new result didn’t change too much with this study omitted, and TET2 mutation still conferred an unfavorable impact on OS in AML patients.